Itraconazole Oral Absorption

Status Completed

Clinical Trial Summary

For tablets to be absorbed, the drug must dissolve after being swallowed. Drugs with low solubility sometimes require the inert ingredients in tablets to help the drug dissolve after being swallowed. This study uses itraconazole as an example drug with low solubility. Itraconazole tablets with different inert ingredients and manufacturing will be administered to healthy volunteers to see if the different inert ingredients and manufacturing impact drug absorption.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04035187
Study type	Interventional
Source	University of Maryland, Baltimore
Contact
Status	Completed
Phase	Phase 4
Start date	February 10, 2020
Completion date	May 21, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03641131` - Ampholipad Real-World Data in Taiwan
Not yet recruiting	`NCT03292224` - Systemic Fungal Infections in ICU Patients	N/A
Completed	`NCT01371656` - Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation	Phase 3
Completed	`NCT00936117` - Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia	Phase 2
Completed	`NCT00740389` - TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.	Phase 1
Completed	`NCT03857399` - Empiric Therapy of Patients With Persistent Fever and Agranulocytosis Using Caspofungin	Phase 2
Not yet recruiting	`NCT04215458` - Microbiota in Skin and Mucosa of Patients With Inflammatory Skin Diseases	N/A
Completed	`NCT03667690` - Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis	Phase 3
Completed	`NCT02957929` - Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally	Phase 1
Completed	`NCT01419678` - Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients	N/A
Recruiting	`NCT00333645` - Prophylaxis With Caspofungin in High-Risk Liver Transplantation	Phase 2
Not yet recruiting	`NCT03650439` - Fungal Infections in Patients With Hematological Malignancies
Completed	`NCT01303549` - Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients	Phase 4
Completed	`NCT00811642` - Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551)	Phase 3
Withdrawn	`NCT00430469` - Safety of hLF1-11 for the Treatment of Infectious Complications Among HSCT Recipients	Phase 1/Phase 2
Terminated	`NCT00386997` - ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia	Phase 4
Completed	`NCT00514358` - Fluconazole Pharmacokinetics in Infants	Phase 1
Completed	`NCT04166669` - A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001	Phase 1
Recruiting	`NCT05150327` - Multicenter Cohort Study of Invasive Fungal Filamentous Fungal Infections in Liver Transplant Patients
Completed	`NCT02387983` - Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117)	Phase 1